Pricing Log in Create free account

Abeona Therapeutics Inc. (ABEO) vs Fate Therapeutics, Inc. (FATE)

Abeona Therapeutics Inc. and Fate Therapeutics, Inc. are both Biotechnology companies. Abeona Therapeutics Inc. and Fate Therapeutics, Inc. are of similar size ($238.5M and $223.1M). Abeona Therapeutics Inc. grew revenue faster over the last twelve months: 427.5% against −23.4%. Abeona Therapeutics Inc. has the higher net margin (−242.6% vs −1,941.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 17 metrics below, Abeona Therapeutics Inc. leads on 13 and Fate Therapeutics, Inc. on 4.

Valuation

Metric ABEO FATE Biotechnology median
P/E n/m n/m 10.60
P/S 9.18 34.13 9.40
P/B 1.86 1.44 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 4.09 14.04 9.02
Earnings yield (28.06%) (57.07%) (32.88%)
Free cash flow yield (34.27%) (47.59%) (23.13%)

Profitability

Metric ABEO FATE Biotechnology median
Gross margin 66.03% 100.00% 68.51%
Operating margin (322.59%) (2,058.08%) 0.00%
Net margin (242.62%) (1,941.09%) 0.00%
Free cash flow margin (314.53%) (1,624.06%) 0.00%
Return on equity (43.13%) (60.75%) (51.96%)
Return on assets (29.54%) (39.89%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ABEO FATE Biotechnology median
Revenue growth (TTM) 427.47% (23.36%) 6.76%
EPS growth (last fiscal year) 165.16% 29.88% 29.88%
Revenue growth, 5-year CAGR 14.19% (26.71%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ABEO FATE Biotechnology median
Debt to equity 0.12 0.00 0.00
Current ratio 6.63 4.85 4.97
Net debt to EBITDA 2.00 1.47 1.01

Dividend

Metric ABEO FATE Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ABEO FATE Biotechnology median
Market cap 238.46m 223.08m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack